emraclidine
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 2, 2022 (NCT05644977)
Timeline
Indications
Mechanism of action
PAM antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)c2c(n1)CN(C(=O)CC1CN(c3ccnc(C(F)(F)F)c3)C1)C2- Mol. weight
- 390.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314557 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07219030 | Phase 1 | Oct 8, 2025 | AbbVie |
| NCT07145918 | Phase 2 | Aug 4, 2025 | AbbVie |
| NCT06366243 | Phase 1 | May 10, 2024 | Cerevel Therapeutics, LLC |
| NCT06301971 | Phase 1 | Mar 4, 2024 | Cerevel Therapeutics, LLC |
| NCT05965219 | Phase 1 | Aug 15, 2023 | Cerevel Therapeutics, LLC |
| NCT05940402 | Phase 1 | Jul 24, 2023 | Cerevel Therapeutics, LLC |
| NCT05935033 | Phase 1 | Jun 30, 2023 | Cerevel Therapeutics, LLC |
| NCT05915546 | Phase 1 | Jun 8, 2023 | Cerevel Therapeutics, LLC |
| NCT05644977 | Phase 1 | Dec 2, 2022 | Cerevel Therapeutics, LLC |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cerevel Therapeutics, LLC | For profit | 7 | 7 | 1 | 2022 |
| AbbVie | For profit | 2 | 2 | 2 | 2025 |
2 organizations
Page 1 / 1